rethinkPeptides Search
Menu
Study breakdown

A New Heart Damage Marker Combined With BNP Improves Risk Assessment in Dialysis Patients

Cross SectionalModerate evidence
The takeaway

The ratio of heart-type fatty acid-binding protein (hFABP) to myoglobin, combined with BNP, improved detection of cardiac damage and volume overload in dialysis patients beyond either marker alone.

Multi-marker improvement

No single marker was perfect in dialysis patients — combining hFABP/myoglobin ratio + BNP captured both damage AND overload better than any alone

What the researchers found

The hFABP/myoglobin ratio combined with BNP improved detection of cardiac damage and volume overload in dialysis patients, providing a multi-marker approach that overcomes renal clearance confounding of individual markers.

Why it matters

Single biomarkers have limitations in kidney failure patients. Multi-marker approaches that account for renal confounding improve diagnostic accuracy for this extremely high-risk population.

How the study worked

Cross-sectional study in dialysis patients. hFABP, myoglobin, BNP, ANP, and cardiac function parameters measured. The hFABP/myoglobin ratio developed to normalize for renal clearance effects.

What this study cannot tell us

Cross-sectional design. The specific hFABP/myoglobin ratio cutoffs need validation. Dialysis timing affects all markers.

How to read the evidence

Moderate evidence from a comparative biomarker study in a clinically challenging population with novel ratio development.

When this study was published

Published in 2003. Multi-marker cardiac assessment in renal failure patients has evolved with additional novel biomarkers.

The bigger picture

Precision diagnostics in complex patients requires multi-marker panels that account for confounding factors. This approach models how cardiac biomarker science evolves for challenging populations.

Questions still open

  • Should multi-marker panels be standard in dialysis patient cardiac assessment?
  • Does the ratio predict cardiac events in dialysis patients?
  • Can this approach reduce unnecessary cardiac testing in dialysis?

Common questions

Why are heart tests harder in dialysis patients?
Kidney failure changes how the body clears heart markers from the blood, making single measurements unreliable. Using ratios of markers (hFABP/myoglobin) and combining with BNP overcomes this problem.
Should dialysis patients get multiple heart markers?
This study supports yes — no single marker captures both heart damage and fluid overload in dialysis. Combining markers provides a more complete and accurate cardiac risk picture.

Read the original research

Serum ratio of heart-type fatty acid-binding protein to myoglobin. A novel marker of cardiac damage and volume overload in hemodialysis patients.

Nephron. Clinical practice, 93(2), C69-74

Citation

Furuhashi, Masato; Ura, Nobuyuki; Hasegawa, Koichi; Yoshida, Hideaki; Tsuchihashi, Kazufumi; Nakata, Tomoaki; Shimamoto, Kaxuaki. (2003). Serum ratio of heart-type fatty acid-binding protein to myoglobin. A novel marker of cardiac damage and volume overload in hemodialysis patients.. Nephron. Clinical practice, 93(2), C69-74.